Cantor Fitzgerald Comments on AQST FY2025 Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Aquestive Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska forecasts that the company will post earnings of ($0.65) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $17.00 price objective on the stock. The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share.

A number of other equities research analysts also recently weighed in on AQST. Leerink Partners raised their price target on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research note on Friday, December 20th. Finally, JMP Securities reissued a “market outperform” rating and set a $9.00 price target on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $11.00.

Aquestive Therapeutics Trading Up 3.5 %

Shares of NASDAQ AQST opened at $3.21 on Wednesday. Aquestive Therapeutics has a 1-year low of $2.24 and a 1-year high of $6.23. The stock has a fifty day simple moving average of $3.93 and a two-hundred day simple moving average of $4.19. The firm has a market cap of $292.68 million, a price-to-earnings ratio of -7.13 and a beta of 2.71.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The firm had revenue of $13.54 million during the quarter, compared to analysts’ expectations of $12.69 million. During the same period last year, the company posted ($0.03) EPS.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Financial Advocates Investment Management grew its holdings in shares of Aquestive Therapeutics by 14.7% in the third quarter. Financial Advocates Investment Management now owns 39,000 shares of the company’s stock worth $194,000 after acquiring an additional 5,000 shares during the period. nVerses Capital LLC bought a new stake in shares of Aquestive Therapeutics during the 3rd quarter valued at about $28,000. SG Americas Securities LLC increased its position in shares of Aquestive Therapeutics by 28.7% during the 4th quarter. SG Americas Securities LLC now owns 32,966 shares of the company’s stock valued at $117,000 after purchasing an additional 7,347 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Aquestive Therapeutics by 4.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 203,540 shares of the company’s stock worth $1,014,000 after buying an additional 9,268 shares during the last quarter. Finally, Victory Capital Management Inc. bought a new stake in Aquestive Therapeutics during the second quarter valued at approximately $27,000. 32.45% of the stock is owned by institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.